Stay updated on Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page.

Latest updates to the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page
- Check5 days agoChange DetectedThe CheckMate 214 record is displayed with its study design, treatments, eligibility criteria, outcome measures, locations, and supporting documents.SummaryDifference100%

- Check12 days agoChange DetectedThe footer revision number changed from v3.7.2 to v3.8.0; the page still shows a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA sitewide banner announces a terminology change across NIH content, and the site revision advances from v3.7.1 to v3.7.2. The study page continues to display a 403 error rather than study details.SummaryDifference1%

- Check40 days agoChange DetectedThe site footer’s revision number changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the previous visible content and indicating that the study page is currently restricted or unavailable.SummaryDifference0.5%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error page instead of the study content, with the site chrome and a Home button visible. This indicates the trial record is currently inaccessible due to access restrictions.SummaryDifference18%

Stay in the know with updates to Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab-Ipilimumab vs Sunitinib in Advanced RCC Clinical Trial page.